Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus
Authors:
- Chandra MohanCMChandra Mohan
- 11 August 2009
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 13 (10) , 1147-1153
Abstract
(2009). Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus. Expert Opinion on Therapeutic Targets: Vol. 13, No. 10, pp. 1147-1153. doi: 10.1517/14728220903196761Keywords
This publication has 66 references indexed in Scilit:
- CXCR4/CXCL12 Hyperexpression Plays a Pivotal Role in the Pathogenesis of LupusThe Journal of Immunology, 2009
- Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastasesClinical & Experimental Metastasis, 2007
- CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathwayBiochemical and Biophysical Research Communications, 2007
- Multiple-Dose Escalation Study of the Safety, Pharmacokinetics, and Biologic Activity of Oral AMD070, a Selective CXCR4 Receptor Inhibitor, in Human SubjectsAntimicrobial Agents and Chemotherapy, 2007
- Mice deficient in the chemokine receptor CXCR4 exhibit impaired limb innervation and myogenesisMolecular and Cellular Neuroscience, 2005
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar developmentNature, 1998
- The chemokine SDF‐1, stromal cell‐derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4European Journal of Immunology, 1997
- Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1Nature, 1996
- Treatment of Murine Lupus with CTLA4IgScience, 1994